E-5842
E-5842 is a chemical compound that has been investigated for its potential use as a therapeutic agent in the treatment of various neurological and psychiatric disorders. It is primarily known for its action as a selective agonist of the sigma-1 receptor, a protein that is implicated in the modulation of several neurotransmitter systems in the brain.
Pharmacology[edit | edit source]
E-5842 acts as a selective agonist at the sigma-1 receptor, which is a chaperone protein located in the endoplasmic reticulum of cells. The sigma-1 receptor is involved in the regulation of calcium signaling, neuroprotection, and modulation of neurotransmitter release. Activation of this receptor by E-5842 has been shown to have potential therapeutic effects in models of depression, anxiety, and neurodegenerative diseases.
Mechanism of Action[edit | edit source]
The sigma-1 receptor modulates the activity of various ion channels and receptors, including the NMDA receptor, voltage-gated calcium channels, and dopamine receptors. By acting as an agonist at the sigma-1 receptor, E-5842 may enhance neuroplasticity, reduce neuroinflammation, and protect against excitotoxicity, which are beneficial effects in the context of neurological disorders.
Clinical Research[edit | edit source]
E-5842 has been the subject of several preclinical studies and early-phase clinical trials. These studies have explored its efficacy in animal models of schizophrenia, Alzheimer's disease, and Parkinson's disease. While results have been promising, further research is needed to fully understand its therapeutic potential and safety profile in humans.
Potential Applications[edit | edit source]
Due to its action on the sigma-1 receptor, E-5842 is being investigated for its potential use in treating:
- Major depressive disorder
- Generalized anxiety disorder
- Schizophrenia
- Alzheimer's disease
- Parkinson's disease
Safety and Side Effects[edit | edit source]
As with any investigational drug, the safety profile of E-5842 is not fully established. Common side effects observed in early trials include mild gastrointestinal disturbances and transient headaches. Long-term safety data are still being collected.
Also see[edit | edit source]
Template:Drug development footer
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
